Beijing Fino Weikang Biotechnology Co., Ltd.

2023

"Multicolor Immunofluorescence Detection of Pathological Specimens" Included in National Medical Service Charges-Finowicam Fully Helps Multicolor Immunofluorescence Detection

On September 20, the National Health Commission, the State Administration of Traditional Chinese Medicine, and the State Administration for Disease Control and Control jointly launched the "Technical Specifications for National Medical Service Projects (2023 Edition)", which clearly included "multi-color immunofluorescence detection" The "digital fluorescence pathological section scanning" technology is included in the list of national medical service charging items, which indicates that the multi-color immunofluorescence detection technology has been recognized and supported at the national level.

PhenoVision Bio

multicolor immunofluorescence detection

PhenoVision Bio

Digital fluorescence pathological section scanning

PhenoVision Bio

Finowicam Multicolor Immunofluorescence Complete Solution

Beijing Finowaikang Biotechnology Co., Ltd. takes in-situ spatial visualization technology as its core, introduces international advanced equipment and analysis platform, and commercializes detection kits of supporting companies. It focuses on creating a complete set of multi-color immunofluorescence detection solutions for multi-application scenarios, realizes in-situ multi-target detection, visually evaluates the immune microenvironment state in tissue samples, and can provide information such as multi-target co-localization based on traditional pathological detection, to provide a multi-dimensional spatial detection basis for the next generation of pathological diagnosis.

PhenoVision Bio